OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising USD 100 million. The round was led by Novo Holdings, OrbiMed, and F-Prime Capital, with significant contributions from BioTrack Capital, a Chinese investor involved in OnCusp’s seed funding, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, and CJNV BioVentures. The funds will be directed towards the clinical development of CUSP06, an antibody drug conjugate (ADC) targeting CDH6, as well as the expansion of the company’s pipeline and team.
Established in 2021, OnCusp has raised a total of USD 139 million, including a USD 25 million seed financing round led by Sequoia China and BioTrack Capital.The CDH6-targeted ADC, CUSP06, is preparing for a Phase I clinical study in the United States, having received IND approval in the third quarter of 2023.
